Historical record - last NADAC effective date: 4/20/2022
Product Information
DEFERASIROX 360 MG TABLET is a generic product labeled by Amneal Pharmaceuticals NY LLC, priced at $2.1034 per EA under NDC 69238148803. Its NADAC has been published 45 times since Apr 20, 2022.
FDA first approved this application on Dec 27, 2019.
The High Outlier badge above means this manufacturer's average price in the Deferasirox market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
360 mg/1
Manufacturer
Amneal Pharmaceuticals NY LLCNDC
69238148803
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
4/20/2022
Active Ingredients
DEFERASIROXApproval Type
Generic (ANDA)
FDA Application
ANDA210727FDA Approved
12/27/2019
On Market Since
1/2/2020
Pharmacological Classes
Price Statistics
The NADAC for DEFERASIROX 360 MG TABLET has been published 45 times since Apr 20, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1034 per EA |
|---|---|
| All-time high | $2.1034 (Feb 22, 2023) |
| All-time low | $2.1034 (Apr 20, 2022) |
| Median price | $2.1034 |
| Average price | $2.1034 |
| Largest weekly change | 0.0% (Apr 27, 2022) |
| Weeks tracked | 45 |
| Tracking since | Apr 20, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Feb 22, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 41% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals NY LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Deferasirox market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Iron Chelator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEFERASIROX 360 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DEFERASIROX 360 MG TABLET, manufactured by Amneal Pharmaceuticals NY LLC, is $2.1034 per EA (NDC 69238148803), effective Feb 22, 2023.
How has the price of DEFERASIROX 360 MG TABLET changed over time?
Over the history we have for it, the NADAC for DEFERASIROX 360 MG TABLET has held within roughly two percent of its current level. It has been tracked across 45 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for DEFERASIROX 360 MG TABLET?
Since Apr 20, 2022, the NADAC for DEFERASIROX 360 MG TABLET has ranged from a low of $2.1034 (Apr 20, 2022) to a high of $2.1034 (Feb 22, 2023), with a median of $2.1034 per EA.
Are there cheaper alternatives to DEFERASIROX 360 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DEFERASIROX 360 MG TABLET, is $1.2475 per EA — about 41% below DEFERASIROX 360 MG TABLET.
Who manufactures DEFERASIROX 360 MG TABLET?
DEFERASIROX 360 MG TABLET (NDC 69238148803) is labeled by Amneal Pharmaceuticals NY LLC, and CMS classifies it as a generic product.